Biomarkers and Emerging Drug Targets in Neuropsychiatry (Part I)

Page: [5583 - 5583] Pages: 1

  • * (Excluding Mailing and Handling)

[1]
Herzog, S.A.; Brakoulias, V. The role of neurophysiological biomarkers in obsessive-compulsive disorder. Curr. Med. Chem., 2022, 29(35), 5584-5594.
[2]
Palagini, L.; Geoffroy, P.A.; Riemann, D. Sleep markers in psychiatry: Do insomnia and disturbed sleep play as markers of disrupted neuroplasticity in mood disorders? A proposed model. Curr. Med. Chem., 2022, 29(35), 5595-5605.
[3]
Grover, D.; Tom, M.; Maguire, G.; Stahl, S. Polypharmacy- purpose, benefits and limitations. Curr. Med. Chem., 2022, 29(35), 5606-5614.
[4]
Marazziti, D.; Diep, P.T.; Carter, S.; Carbone, M.G. Oxytocin: An old hormone, a novel psychotropic drug and links to viral-induced psychiatric diseases. Curr. Med. Chem., 2022, 29(35), 5615-5687.